Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 ...

Operator Good day, and welcome to the OPKO Health fourth quarter 2024 financial results conference call. All participants will be in a listen-only mode. [Operator instructions] After today's ...

Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response ...

HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in ...

EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, ...

Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigentm with Ultima's UG 100tm sequencing platform to better understand tumor biology ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...